# Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

> **NCT06547476** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib

## Key facts

- **NCT ID:** NCT06547476
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06547476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06547476, "Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06547476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*